Literature DB >> 27385240

Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14.

Stacie B Dusetzina1.   

Abstract

From 2003 to 2014 the proportion of specialty prescription drugs (defined as those reimbursed at $600 or more per thirty-day fill) nearly quadrupled. Over this time period, fills for specialty drugs increased by 198 percent and spending for the drugs increased by 292 percent, as percentages of total drug fills and spending. Median out-of-pocket spending increased by 46 percent for specialty drugs and decreased by 57 percent for nonspecialty drugs during this time. Project HOPE—The People-to-People Health Foundation, Inc.

Keywords:  Health Economics; Pharmaceuticals

Mesh:

Substances:

Year:  2016        PMID: 27385240     DOI: 10.1377/hlthaff.2015.1657

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Trends in Financial Access to Prescription Drugs Among Cancer Survivors.

Authors:  Felisa Gonzales; Zhiyuan Zheng; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

2.  Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

Authors:  Stacie B Dusetzina; Rena M Conti; Nancy L Yu; Peter B Bach
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873

3.  Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.

Authors:  William V Padula; Jeromie Ballreich; Gerard F Anderson
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

4.  Changes in Drug List Prices and Amounts Paid by Patients and Insurers.

Authors:  Eric J Yang; Emilio Galan; Robert Thombley; Andrew Lin; Jaeyun Seo; Chien-Wen Tseng; Jack S Resneck; Peter B Bach; R Adams Dudley
Journal:  JAMA Netw Open       Date:  2020-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.